Pancreatic cancer hides. By the time symptoms surface, the disease has usually spread too far for surgery to help. That grim reality drives the abysmal survival rates we see today.
Enter Audrey Zheng. She is a seventeen-year-old senior at North Allegheny Senior High School in Wexford, Pennsylvania. Instead of complaining about standard high school chemistry labs, she built an innovative bioengineering method to spot early-stage pancreatic ductal adenocarcinoma straight from a basic blood draw.
Her technique caught the attention of the scientific community, earning her a spot as a national finalist in the 2026 Regeneron Science Talent Search. But the accolades matter less than the actual science. Her diagnostic approach correctly identified 87 percent of patients battling the disease and accurately cleared 87.5 percent of healthy individuals.
Let us look at how she pulled it off.
Tracking Microscopic Messages in the Bloodstream
Most people don't realize that our cells constantly shed tiny membrane-covered sacs known as extracellular vesicles. These biological packages carry proteins, lipids, and genetic instructions out into circulation. Think of them as microscopic text messages sent by every tissue in the body.
The problem? Healthy cells release trillions of these vesicles, making tumor-derived signals nearly impossible to isolate using conventional clinical tools. Standard imaging and baseline protein biomarkers simply lack the resolution to catch tiny, localized tumors.
Zheng solved this needle-in-a-haystack problem with chemistry. She engineered a mixture of magnetic nanospheres coated with three distinct antibodies. These antibodies act like molecular magnets, latching specifically onto surface proteins unique to tumor-derived vesicles.
Once the antibodies bind to their targets, an external magnetic field pulls the nanosphere complexes right out of the blood sample. This mechanical separation isolates the suspect vesicles away from trillions of irrelevant background particles.
Targeting Genetic Mutations for Precision
Catching the vesicles is only half the battle. You have to confirm what is actually inside them.
After isolating the targeted packages, Zheng extracted their internal genetic material. She trained her sights on the KRAS gene, a notorious driver mutation present in over 90 percent of pancreatic ductal adenocarcinoma cases.
By analyzing the DNA inside those trapped vesicles for specific KRAS mutations, her system established a strict two-step verification process:
- First, the test screens for cancer-specific surface markers via antibody capture.
- Second, it verifies the internal cargo by hunting for oncogenic DNA mutations.
This dual-layer confirmation keeps false positives surprisingly low. In testing, the method capped false positives at 12.5 percent while retaining a sharp 87 percent sensitivity rate for actual cancer cases.
Catching pancreatic cancer at Stage I or Stage II changes everything. Right now, five-year survival sits below 13 percent because doctors spot the disease far too late. Giving clinicians a reliable, non-invasive blood test to catch tumors before they metastasize transforms a hopeless prognosis into a treatable condition.
Beyond the Lab Bench
Zheng is not your typical single-track academic prodigy. Daughter of Ming Ni and Siyang Zheng, she balances heavy bioengineering research with leadership duties on her high school tennis team and co-presidency of the math and physics club.
Her knack for practical engineering spills over into local community work, too. She founded The Food Lounge Pittsburgh, a non-profit that has organized over 50 volunteer events to support regional food banks and kitchens.
She is already adapting her nanosphere technology for other practical uses. Right now, she is working on a portable sensor designed to detect common food allergens quickly in field settings.
Breakthroughs do not always originate inside corporate pharmaceutical labs backed by millions in venture capital. Sometimes, they start on a student's workbench driven by plain curiosity and a refusal to accept that a devastating disease has to remain unbeatable. Keep an eye on how this magnetic nanosphere method moves from competition display boards to clinical validation trials.
